biote Corp. (BTMD) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several concerns: declining net income and adjusted EBITDA, high attrition rates, and procedural revenue decline. Although there's positive cash flow and growth in the supplements business, the lack of clear guidance on procedural growth and high attrition are worrying. The Q&A highlighted ongoing challenges with sales turnover and attrition, which could continue to pressure the stock. Overall, despite some positives, the negatives outweigh them, leading to a negative sentiment.
Key Financial Performance
Third quarter revenue $48.0 million, a decrease of 6.7%. Procedure revenue declined 10.4% and dietary supplements revenue grew 8.4%. The decline in procedure revenue was primarily due to a slower rate of net new clinic additions and lower procedure volume, impacted by the ongoing transformation of the commercial team. Dietary supplement revenue growth was driven by the continued growth of the e-commerce channel.
Gross profit margin 71.8%, a 150 basis point increase. The improvement was primarily due to cost savings from the vertical integration of the 503(B) manufacturing facility and effective cost management.
Selling, general and administrative expenses $26.2 million, an increase of 9.3%. The increase was due to the timing of the annual marketing event and continued investment in sales and marketing to drive new customer growth.
Net income $9.2 million, compared to $12.7 million in the prior year. The decrease was influenced by a lower gain from changes in the fair value of earn-out liabilities ($2.9 million in 2025 vs. $7.2 million in 2024).
Adjusted EBITDA $12.9 million, a decrease of 20.5%, with an adjusted EBITDA margin of 26.9% (compared to $16.2 million and 31.5% in the prior year). The decrease was due to lower sales, reduced gross profit, and higher operating expenses, including the shift of the annual marketing event to the third quarter of 2025.
Third quarter cash flow from operations $27.6 million, an increase of $14.1 million. This increase reflects improved operational cash generation.
Cash and cash equivalents $28.0 million as of September 30, 2025, compared to $19.6 million as of June 30, 2025. The increase was supported by strong cash flow from operations.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Dietary Supplements Revenue: Increased by 8.4% to $11.2 million, driven by e-commerce channel growth. Expected mid-teens revenue growth for fiscal 2025.
New Product Offerings: Identifying promising opportunities to optimize the portfolio.
Clinic Network Expansion: Continued expansion of clinic network, though impacted by slower pace of new business in the past year.
Sales Team Growth: Approximately 50% of the commercial team joined in the past year. Sales territory coverage is at 75%-80% of the target. Targeted sales rep headcount expected by end of 2025.
Operational Improvements: Implemented changes to internal processes and systems, enhancing data insights, productivity, and execution.
Cost Savings: Achieved through vertical integration of the 503(B) manufacturing facility, improving gross profit margin by 150 basis points to 71.8%.
Strategic Priorities: Focused on accelerating growth from new providers, maximizing value from top-tier clinics, and improving financial performance through accountability and discipline.
Marketing Event: Hosted a major event in Cancun with over 800 attendees and renowned speakers, strengthening relationships and market leadership.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Sales Team Rebuilding: The ongoing process of rebuilding the sales team and enhancing sales and marketing functions has negatively impacted procedure revenue in the near term. Approximately half of the commercial team is new, and the team is currently at 75%-80% of the desired size, which has created a temporary headwind to revenue growth.
Procedure Revenue Decline: Procedure revenue declined by 10.4% in Q3 2025 due to a slower rate of new clinic additions and lower procedure volumes. This decline is attributed to the transformation of the commercial team and slower pace of new business in the prior year.
Increased Operating Expenses: Selling, general, and administrative expenses increased by 9.3%, driven by the timing of the annual marketing event and continued investments in sales and marketing. This has contributed to reduced adjusted EBITDA and margin.
Adjusted EBITDA Decline: Adjusted EBITDA decreased by 20.5% to $12.9 million, with a margin decline from 31.5% to 26.9%, due to lower sales, reduced gross profit, and higher operating expenses.
Strategic Investments and Capital Deployment: The company undertook share repurchases and amended settlement agreements, which required significant capital outflows. While these actions aim to provide long-term value, they represent immediate financial commitments that could impact liquidity.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2025: Biote reiterates its fiscal 2025 revenue guidance of above $190 million.
Adjusted EBITDA Guidance for 2025: Biote reiterates its fiscal 2025 adjusted EBITDA guidance of above $50 million.
Dietary Supplements Revenue Growth: Biote expects mid-teens revenue growth from its dietary supplements business for the 2025 fiscal year.
Sales Team Expansion: Biote anticipates reaching its targeted sales representative headcount by the end of 2025, which is expected to support a return to procedure revenue growth.
Operational Efficiency: Biote plans to leverage improvements in internal processes and systems to enhance operational efficiency and scale its business more effectively.
New Product Offerings: Biote continues to identify and pursue promising new opportunities to optimize its product portfolio, particularly in dietary supplements.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: Biote repurchased approximately 1 million shares of Class A common stock at an average price of $3.28 per share. These repurchases were made within the $20 million common share repurchase program approved by the Board in 2024.
Settlement Agreement Amendments: Biote amended its settlement agreement with Marci Donovitz to repurchase her remaining shares at a savings to the original agreement. Biote paid $12.5 million in October to fully settle the multiyear payment obligation. Additionally, Biote amended its settlement agreement with Dr. Gary Donovitz to repurchase his remaining shares at a savings to the original agreement, agreeing to pay $18.5 million in January 2026 to fully settle the multiyear payment obligation.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the current progress on hiring sales personnel and the associated costs?
A:The company restructured in May, increasing the sales force by 25% and redefining roles. Since then, there has been turnover due to cultural changes, but hiring is progressing well. They are currently at 85% of their target and aim to reach full staffing by year-end to ensure proper customer attention and business growth.
Q:How has the transition impacted the number of procedures?
A:The transition, including the launch of the CDSS system and sales force restructuring, has led to pressures on volumes. This includes slightly higher attrition and slower new customer starts, resulting in lower year-over-year volumes. Efforts are focused on remedying these issues by acquiring new customers and protecting existing business.
Q:What was the motivation behind the Donovitz transaction and its financial impact?
A:The company cannot speculate on the personal motivations of Marci and Gary Donovitz but believes the transaction makes sense due to future cash flow savings. The Marci agreement saved $7.5 million, and the Gary agreement saved $11.1 million, totaling $18.6 million in cash flow savings.
Q:What feedback was received from practitioners at the marketing event, and what are the trends following the event?
A:The marketing event, Sun, Sea, and Biote, was highly successful with nearly 800 attendees. Practitioners praised the speakers, collaboration, and education provided. While it is too early to determine trends post-event, the event is seen as a retention factor and reinforces Biote's leadership in the field. The focus remains on top-tier accounts, and efforts are ongoing to reduce attrition and grow new customer starts.
Q:Has the attrition rate stabilized, and what is driving it?
A:The attrition rate remains elevated at around 8%, similar to Q2 levels, and higher than the historical 5%. Factors include increased competition, the impact of the CDSS launch, and gaps in sales rep coverage. Efforts are being made to improve hiring, training, and customer service to address these issues.
Q:What is the ramp cycle for new sales hires, and how is the supplements business performing?
A:New sales hires typically take 3-6 months to ramp up. The company is accelerating training to reduce this time. The supplements business is performing in line with expectations, with strong growth in the Amazon channel and clinic sales, which account for 70% of the Nutra business. Growth is expected to continue in the mid-teens.
Q:What was the cost of the marketing event, and how is the Asteria conversion progressing?
A:The marketing event cost approximately $1.3 million, slightly less than expected due to sponsorships. Asteria supplied over 50% of procedure fulfillments by the end of September, up from 42% earlier. The conversion process is ongoing and expected to ramp gradually.
Q:What are the terms and additional benefits of the Donovitz transactions?
A:The Marci Donovitz transaction was purely a cash flow restructuring. The Gary Donovitz transaction included extending his non-compete and non-solicitation agreement to April 2027 and dismissing all pending litigation, in addition to cash flow savings.
Q:What are the expectations for procedure revenue growth and trends in Q4?
A:Procedure revenue growth is expected to decline in the high single digits in Q4, impacted by three fewer business days and uncertainty around the holiday period. The supplements business is also expected to see slower growth during this time.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the specific motivations of Marci and Gary Donovitz for the transaction, citing personal reasons. Additionally, they did not provide a clear timeline for when procedural growth trends might improve, stating it was too early to forecast.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Christensen
Corp stockholder
accountability discipline
action
agreement Dr
clinic network
comparison
coverage
earn liability
energy
evidence
hormone optimization
income gain
income share
insight
market opportunity
marketing event
objective
path
payment obligation
practitioner
priority provider
quality capability
rep headcount
sale rep
saving agreement
settlement agreement
share Corp
share repurchase
share saving
size
speaker
state
stockholder income
talent
term clinic
value earn
BTMD Transcript
biote Corp. (BTMD) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call highlights several concerns: a significant decline in procedure revenue, gross profit margin, net income, and adjusted EBITDA. The recall and supply constraints have negatively impacted performance, with ongoing issues expected to affect Q2. Although management expresses confidence in future growth, the lack of specific metrics and continued inventory issues raise doubts. The Q&A session reveals analyst concerns about stabilization and supply constraints. Despite some positive signs, the overall sentiment is negative due to financial declines and uncertainties.
biote Corp. (BTMD) Q4 2025 Earnings Call Transcript
Positive3-11
Biote's earnings call highlights strong financial performance with a 20% revenue increase and improved gross margins. Despite risks related to macroeconomic conditions and regulatory processes, the optimistic guidance for 2025 and strategic plans for growth, including sales team expansion and new product offerings, provide a positive outlook. The absence of negative Q&A feedback further supports a positive sentiment, likely resulting in a stock price increase of 2% to 8% over the next two weeks.
biote Corp. (BTMD) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call reveals several concerns: declining net income and adjusted EBITDA, high attrition rates, and procedural revenue decline. Although there's positive cash flow and growth in the supplements business, the lack of clear guidance on procedural growth and high attrition are worrying. The Q&A highlighted ongoing challenges with sales turnover and attrition, which could continue to pressure the stock. Overall, despite some positives, the negatives outweigh them, leading to a negative sentiment.
biote Corp. (BTMD) Q2 2025 Earnings Call Transcript
Unknown8-7
The earnings call presents mixed signals. Financial metrics show improvement, with increased gross profit margin and reduced SG&A expenses, but cash reserves have decreased. The Q&A reveals concerns about clinic attrition and lack of clear improvement timelines. Despite positive restructuring efforts, tangible results are yet to manifest. The stock price impact is likely neutral as the market waits for clearer signs of recovery.
BTMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
